Data gathered: November 5
Alternative Data for Fresh2 Group
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | N/A | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,458 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Fresh2 Group
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. The company is headquartered in New York, New York.
| Price | $1.70 |
| Target Price | Sign up |
| Volume | 31,990 |
| Market Cap | $5M |
| Year Range | $1.28 - $8.46 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Medical Devices |
In the news
Scotiabank Sticks to Its Hold Rating for FRESNILLO (FNLPF)October 23 - TipRanks |
|
FRESNILLO (FNLPF) Gets a Hold from UBSOctober 23 - TipRanks |
|
 |
Fresh2 Group Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A HearingOctober 17 - Yahoo |
Fresh2 Group gets Nasdaq staff delisting determination, to request hearingOctober 16 - Thefly.com |
|
Fresh2 Group receives delisting letter from NasdaqOctober 16 - Seeking Alpha |
|
Barclays Sticks to Their Hold Rating for FRESNILLO (FNLPF)October 15 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '23 | 620,000 | 510,000 | 110,000 | -4.4M | -4.4M | -7.575 |
| Q1 '23 | 87,000 | 65,000 | 22,000 | -3.4M | -3.4M | -0.390 |
| Q4 '22 | 61,000 | 66,000 | -4,600 | -4.5M | -33M | |
| Q3 '22 | 930,000 | 210,000 | 730,000 | -3.2M | -3.2M | -36.010 |
| Q2 '22 | 3.2M | 950,000 | 2.3M | -33M | -36M | 0.000 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Boston ScientificBSX |
$84.72 0% | 63 |
 |
Edwards LifesciencesEW |
$66.47 0% | 43 |
 |
Intuitive SurgicalISRG |
$507.42 0% | 63 |
 |
MedtronicMDT |
$89.31 0% | 66 |
 |
StrykerSYK |
$366.9 0% | 66 |
Read more about Fresh2 Group (FRES) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Fresh2 Group?
The Market Cap of Fresh2 Group is $5M.
What is the current stock price of Fresh2 Group?
Currently, the price of one share of Fresh2 Group stock is $1.70.
How can I analyze the FRES stock price chart for investment decisions?
The FRES stock price chart above provides a comprehensive visual representation of Fresh2 Group's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Fresh2 Group shares. Our platform offers an up-to-date FRES stock price chart, along with technical data analysis and alternative data insights.
Does FRES offer dividends to its shareholders?
As of our latest update, Fresh2 Group (FRES) does not offer dividends to its shareholders. Investors interested in Fresh2 Group should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Fresh2 Group?
Some of the similar stocks of Fresh2 Group are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.